Roivant Sciences Announces Positive PHocus Trial Results for Mosliciguat

What Happened
Roivant Sciences Ltd. announced on September 8, 2026 via Form 8-K (Item 7.01) that its subsidiary Pulmovant, Inc. reported positive results from the PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The company furnished a press release dated September 8, 2026 as Exhibit 99.1 to the filing.

Key Details

• Date of disclosure: September 8, 2026 (press release attached as Exhibit 99.1).
• Trial name: PHocus; investigational drug: mosliciguat.
• Indication: pulmonary hypertension associated with interstitial lung disease (PH‑ILD).
• Disclosure type: Regulation FD disclosure reported under Item 7.01 of Form 8‑K; exhibits listed under Item 9.01.

Why It Matters
This is a clinical progress update for a drug candidate that could be a material value driver if later-stage results and regulatory reviews are favorable. For investors, the announcement signals a positive development in Pulmovant’s PH‑ILD program but does not provide financial results, regulatory decisions, or detailed efficacy/safety data in the 8‑K itself. Market participants should watch for the full data release, scientific presentations, and any subsequent regulatory filings for more complete information.